# Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

> **NCT02428660** · NA · COMPLETED · sponsor: **Genelex Corporation** · enrollment: 341 (actual)

## Conditions studied

- Cytochrome P450 CYP2D6 Enzyme Deficiency
- Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Cytochrome P450 CYP2C9 Enzyme Deficiency
- Cytochrome P450 CYP2C19 Enzyme Deficiency
- Drug Metabolism, Poor, CYP2D6-RELATED
- Drug Metabolism, Poor, CYP2C19-RELATED
- CYP2D6 Polymorphism

## Interventions

- **GENETIC:** Pharmacogenetic testing
- **OTHER:** Software-based drug & gene interaction risk analysis
- **OTHER:** MTM

## Key facts

- **NCT ID:** NCT02428660
- **Lead sponsor:** Genelex Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428660, "Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02428660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*